CSBRCHAMPIONS ONCOLOGY, INC.

Nasdaq championsoncology.com


$ 4.86 $ -0.13 (-2.62 %)    

Thursday, 09-May-2024 11:59:06 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 4.83
$ 4.86
$ 4.75 x 100
$ 0.00 x 0
$ 4.86 - $ 4.86
$ 4.17 - $ 7.32
483
na
65.66M
$ 0.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-14-2024 01-31-2024 10-Q
2 12-13-2023 10-31-2023 10-Q
3 09-13-2023 07-31-2023 10-Q
4 07-24-2023 04-30-2023 10-K
5 03-16-2023 01-31-2023 10-Q
6 12-13-2022 10-31-2022 10-Q
7 09-12-2022 07-31-2022 10-Q
8 07-22-2022 04-30-2022 10-K
9 03-15-2022 01-31-2022 10-Q
10 12-13-2021 10-31-2021 10-Q
11 09-13-2021 07-31-2021 10-Q
12 07-26-2021 04-30-2021 10-K
13 03-15-2021 01-31-2021 10-Q
14 12-14-2020 10-31-2020 10-Q
15 09-14-2020 07-31-2020 10-Q
16 07-28-2020 04-30-2020 10-K
17 03-16-2020 01-31-2020 10-Q
18 12-16-2019 10-31-2019 10-Q
19 09-16-2019 07-31-2019 10-Q
20 07-29-2019 04-30-2019 10-K
21 03-18-2019 01-31-2019 10-Q
22 12-17-2018 10-31-2018 10-Q
23 09-14-2018 07-31-2018 10-Q
24 07-30-2018 04-30-2018 10-K
25 03-19-2018 01-31-2018 10-Q
26 12-15-2017 10-31-2017 10-Q
27 09-14-2017 07-31-2017 10-Q
28 07-28-2017 04-30-2017 10-K
29 03-17-2017 01-31-2017 10-Q
30 12-14-2016 10-31-2016 10-Q
31 09-14-2016 07-31-2016 10-Q
32 07-29-2016 04-30-2016 10-K
33 03-16-2016 01-31-2016 10-Q
34 12-15-2015 10-31-2015 10-Q
35 09-11-2015 07-31-2015 10-Q
36 07-29-2015 04-30-2015 10-K
37 03-17-2015 01-31-2015 10-Q
38 12-15-2014 10-31-2014 10-Q
39 09-12-2014 07-31-2014 10-Q
40 07-28-2014 04-30-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 craig-hallum-downgrades-champions-oncology-to-hold

Craig-Hallum analyst Matt Hewitt downgrades Champions Oncology (NASDAQ:CSBR) from Buy to Hold.

 champions-oncology-q3-adj-016-misses-015-estimate-sales-1202m-miss-1348m-estimate

Champions Oncology (NASDAQ:CSBR) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of ...

 earnings-scheduled-for-march-12-2024

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.

 insiders-buying-solid-biosciences-and-2-other-stocks

Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.

 insiders-buying-tillys-and-2-other-stocks

Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.

 champions-oncology-revises-fiscal-year-2024-revenue-guidance-to-be-generally-in-line-with-last-years-results

David Miller, CFO of Champions, added, "As we've guided over the last several quarters, the increase in study cancellat...

 champions-oncology-q2-eps-015-down-from-001-yoy-sales-1160m-down-from-1428m-yoy

Champions Oncology (NASDAQ:CSBR) reported quarterly losses of $(0.15) per share. This is a 1600 percent decrease over earnings ...

 earnings-scheduled-for-december-12-2023

Companies Reporting Before The Bell • CSP (NASDAQ:CSPI) is likely to report earnings for its fourth quarter.

 johnson-controls-oracle-and-3-stocks-to-watch-heading-into-tuesday

With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as fo...

 investor-optimism-improves-further-ahead-of-inflation-data-dow-gains-for-third-straight-day

The CNN Money Fear and Greed index showed further improvement in overall market sentiment, while the index remained in the "...

 champions-oncologys-european-research-operations-site-receives-iso-90012015-accreditation-and-ats-certification

Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end onc...

 roth-mkm-maintains-buy-on-champions-oncology-lowers-price-target-to-75

Roth MKM analyst Scott Henry maintains Champions Oncology (NASDAQ:CSBR) with a Buy and lowers the price target from $9 to $7.5.

 champions-oncology-q1-eps-016-misses-010-estimate-sales-1260m-miss-1306m-estimate

Champions Oncology (NASDAQ:CSBR) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of ...

 earnings-scheduled-for-september-13-2023

Companies Reporting Before The Bell • Cracker Barrel Old (NASDAQ:CBRL) is likely to report quarterly earnings at $1.61 per sha...

 champions-oncology-announces-a-multi-year-agreement-and-strategic-collaboration-with-biovolume-to-transform-reproducibility-in-preclinical-oncology-efficacy-studies

 Champions Oncology, Inc. (NASDAQ:CSBR), a leading global preclinical and clinical research services provider that offers end-t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION